生物技术公司诺瓦瓦克斯医药(NVAX.US)今日盘中大涨6%,引发了市场的广泛关注。
诺瓦瓦克斯医药专注于开发预防各种疾病的疫苗产品,正处于临床研发阶段。公司与其瑞典子公司合作生产候选疫苗,其疫苗技术被认为可广泛应用于多种人类传染病。因此,市场对该公司疫苗研发前景较为看好,预期其产品线将进一步丰富,从而推动公司长期增长,成为此次股价大涨的主要原因。
不过,该公司最新财报显示净利润为负,盈利能力仍有待进一步改善。但总体来看,市场对其疫苗研发前景的乐观预期是推动股价上涨的主导因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.